- Home
- BCLI vs APTO Comparison
BCLI vs APTO Comparison
Compare BCLI & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- APTO
- Stock Information
- Founded
- BCLI 2000
- APTO 1986
- Country
- BCLI United States
- APTO Canada
- Employees
- BCLI N/A
- APTO N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCLI Health Care
- APTO Health Care
- Exchange
- BCLI Nasdaq
- APTO Nasdaq
- Market Cap
- BCLI 13.5M
- APTO 13.2M
- IPO Year
- BCLI N/A
- APTO N/A
- Fundamental
- Price
- BCLI $1.89
- APTO $0.21
- Analyst Decision
- BCLI Strong Buy
- APTO Strong Buy
- Analyst Count
- BCLI 1
- APTO 3
- Target Price
- BCLI $30.00
- APTO $4.33
- AVG Volume (30 Days)
- BCLI 109.6K
- APTO 19.3M
- Earning Date
- BCLI 11-14-2024
- APTO 11-08-2024
- Dividend Yield
- BCLI N/A
- APTO N/A
- EPS Growth
- BCLI N/A
- APTO N/A
- EPS
- BCLI N/A
- APTO N/A
- Revenue
- BCLI N/A
- APTO N/A
- Revenue This Year
- BCLI N/A
- APTO N/A
- Revenue Next Year
- BCLI N/A
- APTO N/A
- P/E Ratio
- BCLI N/A
- APTO N/A
- Revenue Growth
- BCLI N/A
- APTO N/A
- 52 Week Low
- BCLI $1.05
- APTO $0.13
- 52 Week High
- BCLI $11.85
- APTO $2.30
- Technical
- Relative Strength Index (RSI)
- BCLI 44.80
- APTO 45.54
- Support Level
- BCLI $1.90
- APTO $0.21
- Resistance Level
- BCLI $2.17
- APTO $0.25
- Average True Range (ATR)
- BCLI 0.18
- APTO 0.02
- MACD
- BCLI -0.05
- APTO 0.00
- Stochastic Oscillator
- BCLI 4.76
- APTO 19.86
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.